Research programme: infectious disease vaccines - PaxVax

Drug Profile

Research programme: infectious disease vaccines - PaxVax

Alternative Names: Dengue vaccine - PaxVax; Human papillomavirus infections vaccine - PaxVax; Influenza virus infections vaccine - PaxVax; Malaria vaccine - PaxVax; Poliomyelitis vaccine - PaxVax; Rabies vaccine - PaxVax; Shigella vaccine - PaxVax; Tuberculosis vaccine -PaxVax; Zika virus vaccine - PaxVax

Latest Information Update: 15 Sep 2016

Price : $50

At a glance

  • Originator PaxVax
  • Class Bacterial vaccines; DNA vaccines; Parasitic vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Dengue; Rabies; Zika virus infection
  • No development reported Human papillomavirus infections; Influenza virus infections; Malaria; Poliomyelitis; Shigella infections; Tuberculosis

Most Recent Events

  • 13 Sep 2016 PaxVax in-licenses SPS® formulation technology platform from LEUKOCARE
  • 16 Jul 2016 No recent reports of development identified for research development in Tuberculosis(Prevention) in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for research development in Shigella-infections(Prevention) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top